Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands' Lentigo Lesions With or Without Laser Therapy
NCT ID: NCT03457246
Last Updated: 2018-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2013-05-06
2014-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study for the Evaluation of the Depigmenting Activity of a Cosmetic Product on Spotted Hand Skin
NCT02204436
CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS
NCT07239726
Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions
NCT04202419
Efficacy and Tolerability of the Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins
NCT06234527
Avene Compact Honey for Prevention of Pigmentation From Visible Light
NCT01448122
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The combination of physical and topical therapies may be beneficial to patients. For example, the use of combination topical therapy may be used after cryotherapy as a maintenance therapy to diminish the risk of relapse. Laser therapy is very efficient on visible lesion, but not to prevent lesions apparition. A cosmetic topical depigmenting product may be a support of laser therapy, to prevent lentigos apparition in peri-lesional areas.
Furthermore, Post-inflammatory hyperpigmentation (PIH) is a common adverse effect seen with laser, occurring in approximately 35-40% of patients with Fitzpatrick skin types I-III. Another study related that 28% of study population has post-inflammatory hyperpigmentation. A cosmetic topical depigmenting product may be a support of laser therapy, to prevent possible laser side effect.
Pierre Fabre Dermo-Cosmétique has commercialized a cosmetic product (D-pigment rich texture) for treatment of hyperpigmentation. The aim of this study is to evaluate the efficacy of D-pigment as a support of a laser therapy, through its action on peri-lesional areas.
The expected effect is to show the efficacy of D-pigment in post laser long-term treatment, having a more homogenous skin colour on the D-pigment hand versus the moisturizer hand. The subjects will benefit from a strengthened follow-up by the investigator (one visit every 3 months). After the completion of the study, a complete hands laser treatment will be done for each subject and D-pigment tubes will be offered to the subjects for a 6 months application period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
D-Pigment rich texture
Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by test product ( D-pigment rich texture).
D-Pigment rich texture
Hydrance optimale riche
Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by reference product (Hydrance optimale riche)
Hydrance optimale riche
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-Pigment rich texture
Hydrance optimale riche
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject having signed his/her written informed consent.
* Subject treated by laser therapy in the previous 15 to 30 days
* Subject having 5 to 10 lentigos on the surface of each hands
* Subject having lentigos graded 6 or more on the severity grading scale
* Subject with same lentigo severity in each hand.
Exclusion Criteria
* Subject who has planned to sun expose himself/herself more than 7 days,
* Women with childbearing potential
* Participation to an other clinical trial in the previous month or during the study,
* Subject who is not able to understand the information (for linguistic or psychiatric reasons), to give informed consent,
* Subject who, in the judgement of the investigator, is not likely to be compliant with study-related constraints during the study (daily product application during one year),
* Subject who has forfeited her freedom by administrative or legal decision, or who is under guardianship.
Criteria related to pathologies:
* Hyperpigmentation other than lentigos or other hypermelanosis (post-inflammatory laser or chemical melanosis) on the hands,
* Diabetic subject,
* Chronic or progressive disease which may interfere with the study in the opinion of the investigator,
* Pathology, skin disorder or lesions other than lentigo (psoriasis, atopic dermatitis, mycose, intertrigo, sunburn…) at the dorsum of the hand which could interfere with the evaluation,
* Systemic infectious pathology,
* Hypersensitivity, allergy or intolerance to retinaldehyde or any component of the formulation.
Criteria related to treatments:
* Treatment by depigmenting cosmetic products on the hands within 4 weeks prior to inclusion,
* Treatment by depigmenting treatment containing hydroquinone or any depigmenting drug on the hands (e.g. topical retinoids, topical steroids, …) within 8 weeks prior to inclusion,
* Previous treatment by chemical peels, dermabrasions on the hands within one year prior to inclusion,
* Treatment by photosensitive agents within 8 weeks prior to inclusion.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pierre Fabre Dermo Cosmetique
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giovanni PELLACANI
Role: PRINCIPAL_INVESTIGATOR
Department of Dermatology - University of Modena and Reggio Emilia
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RV4280A2012607
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.